Table1.

Significant pathways with adjusted p-value < 0.001.

Terms	Count	adjusted p-value	Genes
Ribosome	36	7.4E-27	RPL4, RPL31, MRPS11, RPL11, MRPL36, MRPL15, RPL9, MRPL35, RPL6, MRPL32, RPL7, MRPL11, MRPL20, MRPL3, RPS17, MRPL1, RPL36AL, RPL35, RPL17, RPL39, RPL41, RPS7, RPL23, MRPL27, MRPS21, RPL35A, RPS3A, MRPL22, MRPL30, RPS27, RPL37A, FAU, RPL26, RPS21, RPL26L1, RPS24
Oxidative phosphorylation	29	8.3E-19	COX7B, NDUFB8, NDUFB7, NDUFB10, UQCRB, NDUFA11, NDUFA12, COX17, NDUFB3, NDUFB2, ATP5C1, ATP5J, COX7A2, ATP5I, ATP5H, COX6A1, ATP5O, COX5B, COX7C, UQCRH, NDUFV2, NDUFA4, NDUFA1, COX6C, UQCRHL, ATP5J2, UQCRQ, NDUFS5, NDUFS4
Parkinson's disease	26	5.18E-15	COX7B, NDUFB8, NDUFB7, NDUFB10, UQCRB, NDUFA11, NDUFA12, NDUFB3, NDUFB2, ATP5C1, ATP5J,COX7A2, ATP5H, COX6A1, ATP5O, COX5B, COX7C, UQCRH, NDUFV2, NDUFA4, NDUFA1, COX6C, UQCRHL, UQCRQ, NDUFS5, NDUFS4
Huntington's disease	28	1.1E-13	COX7B, NDUFB8, NDUFB7, NDUFA11, NDUFB10, UQCRB, NDUFA12, NDUFB3, NDUFB2, ATP5C1, CLTA, ATP5J, COX7A2, ATP5H, COX5B, COX6A1, ATP5O, COX7C, UQCRH, NDUFV2, NDUFA4, NDUFA1, COX6C, UQCRHL, UQCRQ, NDUFS5, NDUFS4, TAF4B
Alzheimer's disease	26	2.8E-13	COX7B, NDUFB8, NDUFB7, NDUFB10, UQCRB, NDUFA11, NDUFA12, NDUFB3, NDUFB2, ATP5C1, ATP5J, COX7A2, ATP5H, COX6A1, ATP5O, COX5B, COX7C, UQCRH, NDUFV2, NDUFA4, NDUFA1, COX6C, UQCRHL, UQCRQ, NDUFS5, NDUFS4
Non-alcoholic fatty liver disease (NAFLD)	22	1.5E-10	COX7B, NDUFB8, NDUFB7, NDUFB10, UQCRB, NDUFA11, NDUFA4, NDUFA12, NDUFB3, NDUFB2, NDUFA1, COX7A2, COX6A1, COX6C, COX5B, COX7C, UQCRH, UQCRHL, UQCRQ, NDUFS5, NDUFS4, NDUFV2
Spliceosome	13	5.4 E-4	SF3B5, SF3B6, BUD31, LSM5, LSM3, PQBP1, LSM7, PRPF18, SNRPD1, TRA2B, SNRPG, SNRNP27, SNRPF
Cardiac muscle contraction	10	5.2E-04	COX7B, UQCRB, UQCRQ, COX7A2, COX6C, COX6A1, COX5B, COX7C, UQCRHL, UQCRH